Learn More

Archive

US Officially Recognizes Medical Use and Safety of Cannabis: The Top 6 Things to Know About Schedule III and the Process Ahead

By Shawn Hauser
Aug 31, 2023

The federal government formally acknowledged the medical use and low potential of abuse for cannabis, with the US Department of Health and Human Services recommending that cannabis be rescheduled to Schedule III under the Controlled Substances Act. While placement in Schedule III still criminalizes commercial cannabis activity at the federal level, it is a significant step on the path to ending prohibition. This rescheduling would eliminate the application of 280E tax penalties, reduce the level of criminal liability for cannabis-related activity, reduce barriers to research, legitimize the industry through gaining credibility and engagement by physicians and the medical community, and support a growing industry for the American economy.

Read More

Forming Psychedelic Companies: 10 Lessons from the Cannabis Industry

By Charles Alovisetti
Mar 22, 2023

A new industry is emerging in the United States, and entrepreneurs in the psychedelics space must make critical decisions at the onset of new ventures regarding how to set up and structure their new businesses. Luckily, we have access to another industry with a complex legal framework and a patchwork of different state laws: cannabis. And after forming hundreds of cannabis companies with clients over the past decade, Vicente LLP has lessons to be shared.

Read More

President Biden's Cannabis Scheduling Directive: Part 3

By Shane Pennington
Nov 9, 2022

What outcomes are possible from the impending administrative process to reconsider cannabis’s schedule I status? What are the implications of those various possible outcomes? And how should we all proceed in light of it all?

Read More

President Biden's Cannabis Scheduling Directive: Part 2

By Shane Pennington
Oct 21, 2022

To appreciate the gravity of the President’s scheduling directive and what could happen next, you need to understand (1) how the administrative process the President has set in motion will actually work and (2) how the agencies in charge have used it to affirm and reaffirm cannabis’s schedule I1 status repeatedly throughout the Comprehensive Drug Abuse Prevention and Control Act of 1970’s (“CSA”) history. Those topics are covered in this article. 

Read More

The ESG Threat by Shareholders and Proxy Challenges

By Marc Ross
Sep 7, 2022

Socially responsible investors and activist board members have been throwing their ESG weight around during the last few proxy seasons at annual shareholder meetings. They demand action on climate change, diverse boards and senior leadership, restrict campaign donations, divestment in specific industries, and request measurement, benchmarking, and reporting of comprehensive ESG impacts.

Read More

ABA Global Business of Cannabis Conference is Coming to Denver

Nov 9, 2021

The American Bar Association's International Law Section will host its first annual Global Business of Cannabis Conference in Denver, Colorado from November 10-12, 2021. Marc Ross is slated to join the panel "The Environmental Impact of Cannabis Cultivation: Does Legalization Make a Difference?"

Read More

[Webinar] Impact and ESG in the Cannabis Industry

Jun 15, 2021

Watch this recorded session to meet the new VS Impact & ESG team, learn more about this emerging business priority, and how to start planning and measuring your ESG practice – including Corporate Social Responsibility programs, meaningful Diversity, Equity & Inclusion efforts, environmental sustainability, and community and employee engagement.

Read More